Literature DB >> 1689367

Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus.

A D Barrett1, J H Mathews, B R Miller, A R Medlen, T N Ledger, J T Roehrig.   

Abstract

Eight monoclonal antibodies (MAbs) prepared against the flaviviruses Saint Louis encephalitis, dengue 2 and dengue 3 viruses all recognized epitopes on the envelope protein of the prototype flavivirus, yellow fever (YF) virus. Three of these MAbs with flavivirus group-common specificity and two MAbs with a flavivirus-subgroup specificity were found to distinguish wild-type YF viruses from YF 17D-204 vaccine virus, but not from the closely related 17DD vaccine virus, nor from the French neurotropic vaccine virus. This pattern of reactivity was seen only with viruses grown in Aedes albopictus C6/36 cells and not with viruses grown in vertebrate cells (SW13 and Vero cells), where all five MAbs recognized epitopes on both wild-type and 17D-204 viruses. Examination of adult A. aegypti mosquitoes infected with the same YF viruses as above gave a different pattern of results to those in C6/36 cells. Thus, epitope expression differs between mammalian and arthropod cells and between arthropod cells in vitro and in vivo. Neutralization tests showed that all five MAbs would neutralize wild-type Asibi virus grown in SW13 cells, but not Asibi virus grown in C6/36 cells, nor 17D-204 vaccine virus grown in either cell type. Therefore, it is concluded that when YF virus is grown in mosquito cells, wild-type virus is antigenically and biologically distinct from the 17D-204 vaccine virus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689367     DOI: 10.1099/0022-1317-71-1-13

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.

Authors:  B K Sil; L M Dunster; T N Ledger; M R Wills; P D Minor; A D Barrett
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  A synthetic peptide to the E glycoprotein of Murray Valley encephalitis virus defines multiple virus-reactive T- and B-cell epitopes.

Authors:  J H Mathews; J T Roehrig; J R Brubaker; A R Hunt; J E Allan
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies.

Authors:  E Simantini; K Banerjee
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Authors:  Anabelle Lefeuvre; Philippe Marianneau; Vincent Deubel
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

6.  Heterologous Protection against Asian Zika Virus Challenge in Rhesus Macaques.

Authors:  Matthew T Aliota; Dawn M Dudley; Christina M Newman; Emma L Mohr; Dane D Gellerup; Meghan E Breitbach; Connor R Buechler; Mustafa N Rasheed; Mariel S Mohns; Andrea M Weiler; Gabrielle L Barry; Kim L Weisgrau; Josh A Eudailey; Eva G Rakasz; Logan J Vosler; Jennifer Post; Saverio Capuano; Thaddeus G Golos; Sallie R Permar; Jorge E Osorio; Thomas C Friedrich; Shelby L O'Connor; David H O'Connor
Journal:  PLoS Negl Trop Dis       Date:  2016-12-02

Review 7.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

8.  Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism.

Authors:  Emily H Davis; Binbin Wang; Mellodee White; Yan-Jang S Huang; Vanessa V Sarathy; Tian Wang; Nigel Bourne; Stephen Higgs; Alan D T Barrett
Journal:  NPJ Vaccines       Date:  2022-03-23       Impact factor: 9.399

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.